Hematological Changes in Sudanese Patients with Falciparum Malaria Attending Elnihoud Teaching Hospital


Backgrounds: Malaria is a major public health problem in the tropical and subtropical areas of the world, including Africa. Most cases of malaria in Africa are caused by Plasmodium falciparum. Objectives: This study was aimed to assess the hematological changes in patient with falciparum malaria and to estimate the incidence of leucopenia, thrombocytopenia, and its response to anti-malaria therapy, and to correlate the association of the hematological changes with P. falciparum-positive (study group) and P. falciparumnegative (control group).

Methodology: A total of 453 participants (353 cases and 100 as control group) were enrolled in this study, all of them were randomly selected from Elnihoud Teaching Hospital, Elnihoud Locality, West Kordufan State, Sudan. Questionnaire was filled by every participant and thick and thin blood films for malaria were prepared and stained by giemsa stain and the CBC was done by sysmex automated hematological analyzer.

Results: Thrombocytopenia, leucopenia, microcytic hypochromic red blood cells and relative lymphocytosis have significant association with falciparum malaria with Pvalues 0.008, 0.001, 0.008, and 0.004, respectively.

Conclusion: Patients with thrombocytopenia and/or leucopenia with malaria should receive anti-malaria therapy and follow-up by CBC, and shouldn’t be hurried for a bone marrow examination.

[1] Kidist. M and Zerihun, Z. (2016). Thrombocytopenia as marker for the diagnosis of malaria among malaria suspected patients in Arba Minch Health Center, Gamo Gofa Zone, Southern Ethiopia: a cross-sectional study. African Journal of Science and Research, vol. 5, no. 1, pp. 61–64.

[2] Howes, R., Reiner, R., Battle, K., et al. (2015). Plasmodium vivax transmission in Africa. PLOS Neglected Tropical Diseases, vol. 9, no. 11, e0004222.

[3] WHO. (2018). World Malaria Report. National Malaria Programme.

[4] Bhupen, B., Prasanta, K., Krysh, G., et al. (2016). Acute pancreatitis in a patient with complicated falciparum malaria. Journal of Clinical and Diagnostic Research, vol. 10, no. 1, pp. 18–20.

[5] Himanshu, A. and Seema, S. (2012). Thrombocytopenia in P. vivax malaria. NJIRM, vol. 2, no. 3.

[6] Jadhav, U., Patkar, V., and Kadam, N. (2004). Thrombocytopenia in malaria-correlation with severity and type of malaria. Journal of the Association of Physicians of India, vol. 52, pp. 615–618.

[7] Mast, Q., Groof, E., and Lenting, P. (2007). Thrombocytopenia and release of activated von Willebrand factor during early malaria. Journal of Infectious Diseases, vol. 196, pp. 622–628.

[8] WHO. (2010). Guidelines for the Treatment of Malaria. World Health Organization.

[9] Mast, Q., Groot, P., Heerde, W., et al. (2010) Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy. British Journal of Haematology, vol. 151, pp. 495–503.

[10] Kreil, A., Wenisch, C., Brittenham, G., et al. (2000). Thrombopoietin in plasmodium falciparum malaria. British Journal of Haematology, vol. 109, pp. 534–536.

[11] Lowenberg, C., Charunwatthana, P., Cohen, S., et al. (2010). Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. Thrombosis and Haemostasis, vol. 103, pp. 181–187.

[12] Saravu, K., Rishikesh, K., and Kamath, A. (2014). Determinants of mortality, intensive care requirement and prolonged hospitalization in malaria – a tertiary care hospital based cohort study from South-Western India. Malaria Journal, vol. 13, no. 1, p. 370.

[13] Divya, R. and Sudha, R. (2016). A clinical study of falciparum malaria with special reference to its complications among malaria patients. Journal of Health Sciences, vol. 1, no. 4.

[14] Ladhani, S., Lowe, B., Cole, A. O., et al. (2002). Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome. British Journal of Haematology, vol. 119, no. 3, pp. 839–847.